A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information

Enrolling by invitationOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

February 3, 2023

Primary Completion Date

December 15, 2032

Study Completion Date

December 15, 2032

Conditions
Adult Growth Hormone Deficiency
Interventions
DRUG

Somapacitan

Sogroya therapy in participants with AGHD.

Trial Locations (46)

1000

UKC Ljubljana, Endocrinology and Diabetes, Ljubljana

10017

NYU Langone Health, New York

10021

Cornell University, New York

18034

St Lukes Physician Group, Center Valley

21287

Johns Hopkins University, Baltimore

26122

Medicover MVZ Oldenburg, Oldenburg

Medicover Oldenburg MVZ, Oldenburg

27514

University of North Carolina, Chapel Hill

27834

Physicians East Endocrinology, Greenville

30318

Atlanta Diabetes Associates, Atlanta

52074

Uniklinik Aachen - Endokrinologie und Diabetologie, Aachen

55131

Universitätsmedizin der JGU Mainz - Endokrinologie und Stoffwechselerkrankungen, Mainz

59000

CHU LILLE - HOPITAL CLAUDE HURIEZ - Service d'endocrinologie et diabétologie, Lille

59046

King Fahad Medical City, Riyadh

60596

Endokrinologikum Frankfurt, Frankfurt am Main

63110

Washington University, St Louis

68198

UNMC, Omaha

69500

HCL - HOPITAL LOUIS PRADEL - Service d'endocrinologie, Bron

75013

APHP - LA PITIE SALPETRIERE - Service endrocrinologie et medecine de la reproduction, Paris

75231

Revival Research Institute, LLC, Dallas

78231

Consano Clinical Research, LLC, Shavano Park

79935

EP Premier Medical Group PA, El Paso

80045

Anschutz Outpatient Pavilion, Aurora

80336

LMU Klinikum Großhadern München - Med. Klinik, München

81667

Medicover Neuroendokrinologie MVZ München, München

Medicover Neuroendokrinologie MVZ, München

85013

Barrow Neurological Institute, Phoenix

89148

Palm Research Center Inc-Vegas, Las Vegas

89511

Northern Nevada Endocrinology, Reno

90033

Keck Medical Center of USC - Outpatient Clinic, Los Angeles

90095

UCLA Health, Los Angeles

92683

Advanced Rx Clinical Research, Westminster

94304

Stanford Univ School of Med, Palo Alto

97080

Universitätsklinikum Würzburg - Zentrum für Innere Medizin (ZIM), Würzburg

97239

Oregon Health & Science University, Portland

02111

Tufts Medical Center, Boston

02114

Massachusetts General Hospital, Boston

02115

Brigham & Women's Hospital, Boston

98108-1597

Puget Sound VA, University of Washington, Seattle

06120

Universitätsklinikum Halle - Innere Medizin III, Halle

818-8502

Fukuoka University Chikushi Hospital_Endocrinology and Diabetes Mellitus, Chikushino-shi, Fukuoka

890-8520

Kagoshima University Hospital_Neurosurgery, Kagoshima-shi, Kagoshima

211-8533

Nippon Medical School Musashikosugi Hospital_Neurological Surgery, Kawasaki-shi, Kanagawa

650-0017

Kobe University Hospital_Diabetes and Endocrinology, Kobe-shi, Hyogo

700-8558

Okayama University Hospital_General Medicine, Okayama-shi, Okayama

534-0021

Osaka City General Hospital_Endocrinology and Diabetes Mellitus, Osaka-shi, Osaka

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05718570 - A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information | Biotech Hunter | Biotech Hunter